The study finds that the new treatment for prostate cancer may delay the treatment of hormones

new Treatment strategy Researchers at the University of California in Los Angeles can introduce new hope to men who have returned prostate cancer after initial treatment.

This approach can also help delay the need for hormonal therapy, which can have stressful side effects.

The results, which were presented at the annual American Association of Radiation Centers (ASTRO) this week, showed that the combination of the target Radio With standard radiotherapy more than weakness, the number of time remains free from the development of the disease.

The new breast cancer drug wins the approval of the FDA after reducing the risk of progress by about 40 %

the study Focus on men With a form of cancer frequency, where the disease returned in only isolated spots. Traditionally, this has been treated with a kind of concentrated radiation called radiotherapy for the body, which is a very accurate type of radiotherapy used to treat tumors in the body.

The team led by the University of California in Los Angeles wanted to determine whether adding the Radioligand treatment that targets PSMA, a radioactive drug that is in the cancer cells, will be more effective, according to a press statement.

The researchers registered 92 men with frequent prostate cancer in the experiment. Half of the radiation was received alone, while the other half received the new drug as well as radiation.

The men who received both remedies remain Cancer -free For nearly 18 months, compared to about seven months of those who received radiation alone.

Click here to register in our health newsletter

“This is the first Random To show that Radioligand, who targets PSMA, can delay progress significantly when adding to radiation directed to a malignant tumor, “said Dr. Ammar Keishhan, Executive Vice President of Radioactive Oncology at the University of California, Los Angeles and study author, Fox News digital.

Kishhan described the work as “a great example of real cooperation between radiology and nuclear medicine.”

Click here to get the Fox News app

One of the largest benefits is the possibility that patients will delay the start of hormonal therapy, according to Keishan. While this next step is common, it often brings side effects such as fatigue and bone loss and Mood changes.

“It gives patients more time before the need for hormonal therapy,” Kishhan said. “Avoid or delay hormonal therapy constantly benefit from the quality of life.”

Despite the improvements, cancer eventually returned to many patients.

“There is always room for improvement,” Kishhan pointed out. “There are still progress events … so there may be ways to do so Improving treatment additional.”

More in health news

The new drug, which is called 177lu-PN2002, has not yet relied on FDA (FDA) for use at this stage of the disease.

At the present time, Kishhan recommends that the men who suffer from their spread Prostate cancer Outside the prostate areas must “search for a consultation with a radiologist to explore options.”